STENOCARE DK-08
Stenocare A/S cultivates, produces, imports, distributes, and sells prescription-based medical cannabis products to patients in Denmark and internationally. It offers medical cannabis oil products, including THC, THC/CBD, and CBD oil products. The company was incorporated in 2017 and is based in Randers, Denmark.
Market Cap & Net Worth: STENOCARE DK-08 (S7C)
STENOCARE DK-08 (F:S7C) has a market capitalization of $6.25 Million (€6.09 Million) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #31718 globally and #3512 in its home market, demonstrating a -14.02% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying STENOCARE DK-08's stock price €0.14 by its total outstanding shares 43195978 (43.20 Million).
STENOCARE DK-08 Market Cap History: 2020 to 2026
STENOCARE DK-08's market capitalization history from 2020 to 2026. Data shows change from $112.62 Million to $6.25 Million (-39.40% CAGR).
STENOCARE DK-08 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how STENOCARE DK-08's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of S7C by Market Capitalization
Companies near STENOCARE DK-08 in the global market cap rankings as of March 18, 2026.
Key companies related to STENOCARE DK-08 by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
STENOCARE DK-08 Historical Marketcap From 2020 to 2026
Between 2020 and today, STENOCARE DK-08's market cap moved from $112.62 Million to $ 6.25 Million, with a yearly change of -39.40%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €6.25 Million | -26.94% |
| 2025 | €8.56 Million | +19.50% |
| 2024 | €7.16 Million | -48.57% |
| 2023 | €13.92 Million | -73.75% |
| 2022 | €53.03 Million | -11.28% |
| 2021 | €59.77 Million | -46.93% |
| 2020 | €112.62 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of STENOCARE DK-08 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.25 Million USD |
| MoneyControl | $6.25 Million USD |
| MarketWatch | $6.25 Million USD |
| marketcap.company | $6.25 Million USD |
| Reuters | $6.25 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.